Farmácia / Notícias da Indústria
Estudo de coorte | Em crianças com síndrome inflamatória multissistêmica (multisystem inflammatory syndrome – MIS-C) associada à Covid-19, o tratamento inicial com imunoglobulina intravenosa (IGIV) e glicocorticoides foi associado com menor risco de disfunção cardiovascular nova ou persistente em comparação ao tratamento com IGIV isolada.
18 Jun, 2021 | 10:40hEditorial: Immunotherapy for MIS-C — IVIG, Glucocorticoids, and Biologics
Entrevista em áudio | Potenciais tratamentos para crianças com síndrome inflamatória multissistêmica (multisystem inflammatory syndrome – MIS-C) associada à Covid-19.
18 Jun, 2021 | 10:38hAudio Interview: Covid-19 in Children – New England Journal of Medicine
M-A | Tratamentos agudos para enxaqueca episódica em adultos.
18 Jun, 2021 | 10:28hAcute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis – JAMA (gratuito por tempo limitado)
Editorial: Acute Treatment for Migraine: Contemporary Treatments and Future Directions (gratuito por tempo limitado)
Comentário no Twitter (fio – clique para saber mais)
Science marches breathlessly forward – or, at least tries to expand its indication.
Anti–calcitonin gene-related peptide antibody infusion, again, vs. placebo.
— Ryan Radecki, MD MS (@emlitofnote) June 17, 2021
Estudo randomizado | Tofacitinibe reduziu o risco de morte ou insuficiência respiratória em pacientes hospitalizados com pneumonia por Covid-19.
17 Jun, 2021 | 11:06hTofacitinib in Patients Hospitalized with Covid-19 Pneumonia – New England Journal of Medicine
Comunicado de imprensa: Data Published in New England Journal of Medicine Shows Pfizer’s Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia
Comentário no Twitter:
Patients who were hospitalized with #COVID19 pneumonia were randomly assigned, at a median of 10 days after symptom onset, to receive tofacitinib or placebo. At 28 days, the risk of death or respiratory failure was lower in the tofacitinib group. #IDTwitter
— NEJM (@NEJM) June 16, 2021
[Preprint] Estudo RECOVERY descobre que a combinação de anticorpo monoclonal Regeneron reduz as mortes de pacientes hospitalizados com COVID que não desenvolveram sua própria resposta imunológica.
17 Jun, 2021 | 11:04hComunicado de imprensa: RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response
Estudo original (preprint): Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – medRxiv
Comentários: Monoclonal antibodies cut risk of dying from COVID-19—but only in some patients – Science E Antibody combo cuts COVID deaths by 20% in very ill seronegative patients – CIDRAP E Regeneron antibody saves lives in some hospitalized Covid patients, study finds – STAT E Expert reaction to press release from the RECOVERY trial reporting that Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response – Science Media Centre
Comentário no Twitter
RECOVERY Pre-print:
In patients hospitalised with COVID-19 but no natural antibody response, monoclonal antibody infusion:
– reduced mortality
– increased speed of discharge
– reduced progression to invasive mechanical ventilation or deathhttps://t.co/rpDk4eUhmm pic.twitter.com/wXegKcDZg8— Martin Landray (@MartinLandray) June 16, 2021
[Comunicado de imprensa – Ainda não publicado] CureVac falha como vacina contra COVID-19 em estudo, com 47% de eficácia.
17 Jun, 2021 | 11:01hCureVac Fails in Pivotal COVID-19 Vaccine Trial With 47% Efficacy – AP / Reuters
Ver também: CureVac’s COVID-19 shot just failed in a large trial, a major setback for the Gates-backed biotech – Insider
Comunicado de imprensa: CureVac provides update on phase 2b/3 trial of first-generation COVID-19 vaccine candidate, CVnCoV
Comentário no Twitter (fio – clique para saber mais)
Bad new for CureVac's vaccine: it didn't make it over the efficacy bar in its 2nd interim analysis – only 47%. Not bad enough to be out for the count – it's 134 events (symptomatic Covid-19) & final is at 185 – but ….1/2 https://t.co/4GsLzgP7AT HT @noviceprize @megtirrell
— Hilda Bastian, PhD (@hildabast) June 16, 2021
Série de casos | 7 casos de miocardite após vacinação baseada em mRNA contra COVID-19.
17 Jun, 2021 | 11:00hMyocarditis after BNT162b2 and mRNA-1273 Vaccination – Circulation
Relacionado: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. E Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. E CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Série de casos | Achados clínicos e de ressonância magnética em 4 casos de miocardite após vacinação baseada em mRNA contra COVID-19.
17 Jun, 2021 | 10:58hComentário: Possible Association Between COVID-19 Vaccine and Myocarditis – American College of Cardiology
Relacionado: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. E Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. E CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Série de casos | Miocardite sintomática aguda em 7 adolescentes após vacinação baseada em mRNA contra COVID-19.
17 Jun, 2021 | 10:57hRelacionado: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. E Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. E CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Revisão sistemática | Segurança e eficácia da metformina em pacientes com função renal reduzida – Segurança e benefício em taxas de filtração glomerular estimada (estimated glomerular filtration rate – eGFR) de 45 mL/min/1,73 m2 ou mais; possivelmente prejudicial em eGFR abaixo de 30 mL/min/1,73 m2.
17 Jun, 2021 | 10:54h
Comentário no Twitter
Safety of metformin for T2 diabetes in people with reduced kidney function
Associated with ⬇️ mortality and no ⬆️ risk of acidosis at an eGFR of > 45
Associated with fewer benefits & possible ⬆️ in the risk of acidosis at an eGFR <30 https://t.co/uOyarn11hM@goKDIGO pic.twitter.com/Ca05gc7FHi
— Kamlesh Khunti (@kamleshkhunti) June 16, 2021